Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to subjects with chronic hepatic impairment and in matched healthy subjects.

Key facts

Study ID
NCT02095587
Run by
SecuraBio
People needed
24
Starts
2014-03-01
Expected to finish
2014-10-01
Last updated by the study team
2021-03-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.